Back
E.02 Safety and Efficacy of ETX101, an Investigational AAV9-based Gene Therapy for SCN1A+ Dravet Syndrome: Results from the POLARIS Phase 1/2 Clinical Trials
Monday, December 7, 2026 at 8:30 AM to 10:45 AM · 2 hr. 15 min. (America/Denver)
Platform
Information
Session ID
PLATE26
Presentation Id
3530615
Event ID
24056
Session Type
Presentation
MD
M. Scott Perry, MD
Head of Neurosciences and Vice President of Faculty Development
Cook Children’s Physician Network
Presentation
Platform E | Anti-Seizure Medications/Clinical Epilepsy
Monday, December 7, 2026 at 8:30 AM to 10:45 AM
Ersida Buraniqi · Children's National Hospital
Anumeha Sheth · Hartford HealthCare Ayer neuroscience institute Comprehensive Epilepsy Center